1. Home
  2. GMAB
  3. GMAB News

Latest Genmab A/S ADS (GMAB) News on June 1, 2025

GMAB

Morningstar Research

a day ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
GMAB

TipRanks

2 days ago

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital

GMAB

MT Newswires

3 days ago

RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
GMAB

GlobeNewswire

5 days ago

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

6 days ago

Transactions in Connection with Share Buy-back Program

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
GMAB

Insider Monkey

9 days ago

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GMAB

GlobeNewswire

10 days ago

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
GMAB

GlobeNewswire

11 days ago

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

12 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

13 days ago

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
GMAB

GlobeNewswire

18 days ago

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

20 days ago

Transactions in Connection with Share Buy-back Program

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
GMAB

GuruFocus.com

23 days ago

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives

GMAB

MT Newswires

24 days ago

Genmab Q1 Earnings, Revenue Increase

Genmab Announces Financial Results for the First Quarter of 2024
GMAB

GlobeNewswire

24 days ago

Genmab Announces Financial Results for the First Quarter of 2024

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

a month ago

Transactions in Connection with Share Buy-back Program

GMAB

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Premarket Friday

GMAB

MT Newswires

a month ago

Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
GMAB

Business Wire

a month ago

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?
GMAB

Insider Monkey

a month ago

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

a month ago

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

a month ago

Transactions in Connection with Share Buy-back Program

GMAB or RGEN: Which Is the Better Value Stock Right Now?
GMAB

Zacks

2 months ago

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Should Value Investors Buy Genmab (GMAB) Stock?
GMAB

Zacks

2 months ago

Should Value Investors Buy Genmab (GMAB) Stock?

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
GMAB

Simply Wall St.

2 months ago

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

GMAB

MT Newswires

2 months ago

Genmab Says Darzalex Q1 Global Net Sales Reach $3.24 Billion

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
GMAB

GlobeNewswire

2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

2 months ago

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction
GMAB

GlobeNewswire

2 months ago

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program
GMAB

GlobeNewswire

2 months ago

Transactions In Connection with Share Buy-back Program

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?
GMAB

Insider Monkey

2 months ago

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
GMAB

GlobeNewswire

2 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?
GMAB

Insider Monkey

2 months ago

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

GMAB

MT Newswires

2 months ago

Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
GMAB

Business Wire

2 months ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program
GMAB

GlobeNewswire

2 months ago

Transactions in connection with share buy-back program

Genmab’s Tivdak approved in Japan for advanced cervical cancer
GMAB

Pharmaceutical Technology

2 months ago

Genmab’s Tivdak approved in Japan for advanced cervical cancer

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
GMAB

Benzinga

2 months ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

GMAB

MT Newswires

2 months ago

Genmab Says Japan Approves Tivdak for Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
GMAB

Business Wire

2 months ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program
GMAB

GlobeNewswire

2 months ago

Genmab Announces Initiation of Share Buy-Back Program

GMAB

MT Newswires

2 months ago

Genmab Denies Trade Secret Misappropriation Claims by AbbVie

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
GMAB

GlobeNewswire

2 months ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab A/S (GMAB): A Bull Case Theory
GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB): A Bull Case Theory

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
GMAB

GlobeNewswire

2 months ago

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

3 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
GMAB

GlobeNewswire

3 months ago

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting
GMAB

GlobeNewswire

3 months ago

Passing of Genmab A/S’ Annual General Meeting

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
GMAB

BioPharma Dive

3 months ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Genmab says J&J not exercising option on HexaBody-CD38
GMAB

TipRanks

3 months ago

Genmab says J&J not exercising option on HexaBody-CD38

GMAB

MT Newswires

3 months ago

William Blair Upgrades Genmab to Outperform From Market Perform

GMAB

Investing.com

3 months ago

Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded

GMAB

MT Newswires

3 months ago

RBC Cuts Price Target on Genmab to DKK2,300 From DKK2,400, Keeps Outperform Rating

GMAB

MT Newswires

3 months ago

Truist Lowers Price Target on Genmab to $45 From $50, Maintains Buy Rating

GMAB

MT Newswires

3 months ago

Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
GMAB

Business Wire

3 months ago

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?
GMAB

Insider Monkey

3 months ago

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

3 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

3 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
GMAB

GlobeNewswire

3 months ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts
GMAB

Insider Monkey

3 months ago

Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?
GMAB

Insider Monkey

3 months ago

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?

GMAB

MT Newswires

3 months ago

Genmab Gets Japanese Regulatory Approval for Follicular Lymphoma Drug

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
GMAB

GlobeNewswire

3 months ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
GMAB

GlobeNewswire

3 months ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
GMAB

Insider Monkey

4 months ago

Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today

GMAB

MT Newswires

4 months ago

Leerink Upgrades Genmab to Outperform From Market Perform, Price Target is $27

Notice to Convene the Annual General Meeting of Genmab A/S
GMAB

GlobeNewswire

4 months ago

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
GMAB

GuruFocus.com

4 months ago

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Genmab Files Annual Report with the U.S. Securities and Exchange Commission
GMAB

GlobeNewswire

4 months ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Publishes 2024 Annual Report
GMAB

GlobeNewswire

4 months ago

Genmab Publishes 2024 Annual Report

Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts
GMAB

Insider Monkey

4 months ago

Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts

Exploring High Growth Tech Stocks In February 2025
GMAB

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks In February 2025

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

4 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Is Genmab (GMAB) the High Growth International Stock to Invest in Now?
GMAB

Insider Monkey

4 months ago

Is Genmab (GMAB) the High Growth International Stock to Invest in Now?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
GMAB

GlobeNewswire

4 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

GMAB vs. QGEN: Which Stock Is the Better Value Option?
GMAB

Zacks

5 months ago

GMAB vs. QGEN: Which Stock Is the Better Value Option?

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know
GMAB

Zacks

5 months ago

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know

Are Investors Undervaluing Genmab (GMAB) Right Now?
GMAB

Zacks

5 months ago

Are Investors Undervaluing Genmab (GMAB) Right Now?

High Growth Tech Stocks To Watch In January 2025
GMAB

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In January 2025

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GMAB

GlobeNewswire

5 months ago

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
GMAB

GlobeNewswire

6 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

GlobeNewswire

6 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

Business Wire

6 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

MT Newswires

6 months ago

Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial

Exploring None's High Growth Tech Stocks With Strong Potential
GMAB

Simply Wall St.

6 months ago

Exploring None's High Growth Tech Stocks With Strong Potential

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
GMAB

Business Wire

6 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GMAB

GlobeNewswire

6 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

6 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
GMAB

GlobeNewswire

6 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?
GMAB

Insider Monkey

6 months ago

Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?
GMAB

Insider Monkey

6 months ago

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?

Genmab to Present at Citi’s Global Healthcare Conference
GMAB

GlobeNewswire

6 months ago

Genmab to Present at Citi’s Global Healthcare Conference

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?
GMAB

Insider Monkey

6 months ago

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

6 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
GMAB

Insider Monkey

7 months ago

Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now

High Growth Tech Stocks To Watch In November 2024
GMAB

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In November 2024

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...
GMAB

GuruFocus.com

7 months ago

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...

GMAB

MT Newswires

7 months ago

Genmab Shares Fall After Reporting Q3 Results

Share on Social Networks: